No country has yet implemented a pilot to ensure access to or the innovation of new antibiotics for multi-drug infections. A team from national health agencies in Norway, with the support of the Innovative Medicine Initiative-funded project DRIVE-AB, designed a model suitable for the national context, including the selection of the antibiotics, the potential value, and the operational model.
Get full access to this article
View all access options for this article.
References
1.
R.Laxminarayanet al., “Antibiotic Resistance: The Need for Global Solutions,”Lancet Infectious Diseases13, no. 12 (2013): 1057-1098.
2.
A. H.Holmeset al., “Understanding the Mechanisms and Drivers of Antimicrobial Resistance,”The Lancet387, no. 10014 (2016): 176-187.
G.Danielet al., “Addressing Antimicrobial Resistance and Stewardship: The Priority Antimicrobial Value and Entry (PAVE) Award,”JAMA318, no. 12 (2017): 1103-1104.
J. F.Mosleyet al., “Ceftazidime-Avibactam (Avycaz): For the Treatment of Complicated Intra-Abdominal and Uri-nary Tract Infections,”Pharmacy and Therapeutics41, no. 8 (2016): 479.
C.Årdalet al., “An Antibiotic's Journey from Marketing Authorization to Use, Norway,”Bulletin of the World Health Organization95, no. 3 (2017): 220.
22.
Central Drugs Standard Control Organization, List of New Drug Approved from 01-01-2017 to Till Date by New Drugs Division, available at <http://cdsco.nic.in/forms/list.aspx?lid=2034&Id=11> (last visited May 8, 2017).
23.
South African Medicine Price Registry, Database Of Medicine Prices 08th May 2017 (2017), available at <http://mpr.gov.za/PublishedDocuments.aspx> (last visited January 11, 2018).
M.-J.Seyaet al., “A First Comparison between the Consumption of and the Need for Opioid Analgesics at Country, Regional, and Global Levels,”Journal of Pain & Palliative Care Pharmacotherapy25, no. 1 (2011): 6-18.
